On December 7, 2021 Tempus, a leader in artificial intelligence and precision medicine, reported six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 – 10 (Press release, Tempus, DEC 7, 2021, View Source [SID1234596576]). The presented findings highlight the unique insights that Tempus’ data and smart diagnostics generate to advance breast cancer research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The research that Tempus is presenting at this year’s symposium underscores the impact that our comprehensive genomic profiling data has on enabling clinicians to make more informed treatment decisions while also powering research for future therapeutics," said Dr. Kimberly Blackwell, Chief Medical Officer at Tempus.

Tempus will present six posters that highlight research to support the use of more personalized treatments for breast cancer patients, conducted with researchers from institutions including Rush University Medical Center, Columbia University Irving Medical Center, and Washington University School of Medicine. Three abstracts selected for poster presentation at SABCS 2021 are highlighted below:

PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using real-world data to describe this unique clinical entity
Overview: This study characterizes the genomic and transcriptomic landscape of advanced or metastatic ILC and co-mutational landscape of CDH1-mutant disease. Researchers retrospectively analyzed 201 de-identified patients with ILC or mixed lobular/ductal histology who were tested via Tempus xT, with abstracted pathology reports. CDH1 mutations were present in 65.3% of all metastatic ILC cases. PIK3CA mutations were more common in patients with CDH1-mutant disease than in patients with CDH1-wildtype disease, suggesting that therapies targeting PIK3CA may be further investigated for their actionability in CDH1-mutant metastatic ILC.
Session: Spotlight Poster Discussion 14
Date: Friday, December 10, 2021
Time: 7:00 am – 8:30 am CT
P3-08-04: The genomic and transcriptomic landscape of PIK3R1-mutated breast cancers
Overview: This study investigates the significance of PIK3R1 mutations in metastatic breast cancer. Researchers retrospectively analyzed a de-identified cohort of 4,296 patients with breast cancer who underwent Tempus xT testing. Patients with PIK3R1 mutations have more frequent mutations associated with poor outcomes and endocrine therapy resistance (PTEN and NF1) compared with patients who are PIK3R1 wild type.
Session: Poster Session 3
Date: Thursday, December 9, 2021
Time: 7:00 am – 8:30 am CT
P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations
Overview: The study provides insight into possible mechanisms of therapeutic resistance to alpelisib/fulvestrant and identifies potential targeted pathways. Researchers retrospectively analyzed a cohort of 2,918 patients with HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations sequenced with Tempus xT, xO or xE. From this cohort, researchers found that there is substantial genomic heterogeneity among PIK3CA-mutated HER2- advanced/metastatic breast cancers, however future studies are needed to assess the prognostic and predictive role of the identified co-mutations and other candidate gene alterations.
Session: Poster Session 3
Date: Thursday, December 9, 2021
Time: 7:00 am – 8:30 am CT
Additional Tempus-affiliated abstracts accepted for poster presentation at SABCS 2021 include:

PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities
Session: Spotlight Poster Discussion 2
Date: Wednesday, December 8, 2021
Time: 7:00 am – 8:30 am CT
GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer
Session: General Session 3
Date: Thursday, December 9, 2021
Time: 10:45 am CT
P5-08-05: Preclinical activity of KB-0742, an oral, highlight selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes
Session: Poster Session 5
Date: Friday, December 10, 2021
Time: 7:00 am – 8:30 am CT
The complete list of Tempus authored and affiliated abstracts can be found on the Tempus publications page.